Histogenics Corporation (NASDAQ:HSGX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Monday. The firm currently has a $2.25 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price target would suggest a potential upside of 9.76% from the stock’s previous close.

According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “

HSGX has been the topic of several other reports. HC Wainwright set a $4.00 target price on Histogenics Corporation and gave the company a “buy” rating in a research note on Friday, August 11th. ValuEngine downgraded Histogenics Corporation from a “sell” rating to a “strong sell” rating in a research note on Monday, August 14th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $4.00 target price on shares of Histogenics Corporation in a research note on Friday, August 11th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $5.31.

Histogenics Corporation (HSGX) traded down 1.44% on Monday, reaching $2.05. The company’s stock had a trading volume of 172,159 shares. The stock’s market cap is $46.10 million. The company’s 50 day moving average price is $1.86 and its 200-day moving average price is $1.77. Histogenics Corporation has a 12-month low of $1.45 and a 12-month high of $3.56.

Histogenics Corporation (NASDAQ:HSGX) last issued its earnings results on Thursday, August 10th. The biotechnology company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.06. During the same period in the previous year, the company earned ($0.61) EPS. On average, equities analysts expect that Histogenics Corporation will post ($1.09) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/18/histogenics-corporation-hsgx-upgraded-to-buy-at-zacks-investment-research.html.

Hedge funds have recently added to or reduced their stakes in the company. Carl Domino Inc boosted its stake in shares of Histogenics Corporation by 24.5% in the 3rd quarter. Carl Domino Inc now owns 34,011 shares of the biotechnology company’s stock worth $110,000 after buying an additional 6,700 shares during the last quarter. First Republic Investment Management Inc. boosted its stake in shares of Histogenics Corporation by 315.2% in the 1st quarter. First Republic Investment Management Inc. now owns 48,455 shares of the biotechnology company’s stock worth $111,000 after buying an additional 36,784 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Histogenics Corporation by 51.1% in the 4th quarter. Renaissance Technologies LLC now owns 99,000 shares of the biotechnology company’s stock worth $165,000 after buying an additional 33,500 shares during the last quarter. Sabby Management LLC boosted its stake in shares of Histogenics Corporation by 28.0% in the 1st quarter. Sabby Management LLC now owns 150,630 shares of the biotechnology company’s stock worth $345,000 after buying an additional 32,965 shares during the last quarter. Finally, Abingworth LLP purchased a new position in shares of Histogenics Corporation in the 3rd quarter worth $543,000. Hedge funds and other institutional investors own 50.08% of the company’s stock.

About Histogenics Corporation

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Get a free copy of the Zacks research report on Histogenics Corporation (HSGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.